ArticleEmerging infectious diseases2025
Population-Based Matched Cohort Study of COVID-19 Healthcare Costs, Ontario, Canada.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estimates of COVID-19-related healthcare costs are key to health system planning, but attributable cost data remain limited. We characterized healthcare costs attributable to COVID-19 through a population-based matched cohort study in Ontario, Canada, by using health administrative data. We matched SARS-CoV-2-positive persons from 2020 to unexposed historical control persons from 2016-2018. We estimated phase-based and survival-adjusted COVID-19-attributable healthcare costs from the health system perspective. We matched 159,817 persons. Mean (95% CI) attributable 10-day costs per person were $1 ($-4 to $6) preindex, $240 ($231-$249) during acute care, $18 ($14-$21) in postacute phases, $3,928 ($3,471-$4,384) in the terminal phase for early deaths, and $1,781 ($1,182-$2,380) for late deaths. Mean cumulative survival-adjusted cost at 360 days was $2,553 ($2,348-$2,756) per person. SARS-CoV-2 infection is associated with substantial long-term healthcare costs, consistent with understanding of post-COVID condition. Determining phase-specific costs can inform budget and pandemic planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.